JP2024546996A5 - - Google Patents
Info
- Publication number
- JP2024546996A5 JP2024546996A5 JP2024536163A JP2024536163A JP2024546996A5 JP 2024546996 A5 JP2024546996 A5 JP 2024546996A5 JP 2024536163 A JP2024536163 A JP 2024536163A JP 2024536163 A JP2024536163 A JP 2024536163A JP 2024546996 A5 JP2024546996 A5 JP 2024546996A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence number
- isoform
- vlcdr1
- vlcdr2
- vlcdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21215028.8 | 2021-12-16 | ||
| EP21215028 | 2021-12-16 | ||
| EP22164796 | 2022-03-28 | ||
| EP22164796.9 | 2022-03-28 | ||
| EP22207926 | 2022-11-16 | ||
| EP22207926.1 | 2022-11-16 | ||
| PCT/EP2022/086452 WO2023111311A1 (en) | 2021-12-16 | 2022-12-16 | Discernible cell surface protein variants of cd117 for use in cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024546996A JP2024546996A (ja) | 2024-12-26 |
| JP2024546996A5 true JP2024546996A5 (enExample) | 2025-12-23 |
Family
ID=84981434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024536163A Pending JP2024546996A (ja) | 2021-12-16 | 2022-12-16 | 細胞療法に使用するためのｃｄ１１７の識別可能な細胞表面タンパク質変異体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250057951A1 (enExample) |
| EP (1) | EP4448573A1 (enExample) |
| JP (1) | JP2024546996A (enExample) |
| KR (1) | KR20240115920A (enExample) |
| AU (1) | AU2022409748A1 (enExample) |
| CA (1) | CA3240527A1 (enExample) |
| IL (1) | IL313568A (enExample) |
| MX (1) | MX2024007317A (enExample) |
| WO (1) | WO2023111311A1 (enExample) |
| ZA (1) | ZA202405110B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023248126A1 (en) * | 2022-06-20 | 2023-12-28 | Crispr Therapeutics Ag | Chimeric antigen receptor specific to cd117 |
| IL317566A (en) * | 2022-07-07 | 2025-02-01 | Cimeio Therapeutics Ag | Antibodies targeting CD117 |
| WO2025231071A1 (en) * | 2024-05-01 | 2025-11-06 | Beam Therapeutics Inc. | Compositions and methods for cell conditioning |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0578774B1 (en) | 1991-04-05 | 1998-07-29 | The Board Of Regents Of The University Of Washington | Monoclonal antibodies to stem cell factor receptors |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
| WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
| US11499168B2 (en) | 2016-04-25 | 2022-11-15 | Universitat Basel | Allele editing and applications thereof |
| LT3535392T (lt) | 2016-11-02 | 2024-04-25 | Universität Basel | Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje |
| RU2019130504A (ru) | 2017-02-28 | 2021-03-30 | Вор Байофарма, Инк. | Композиции и способы ингибирования линиеспецифических белков |
| TWI687227B (zh) * | 2017-10-03 | 2020-03-11 | 生倍科技股份有限公司 | 用於t細胞免疫療法之組合及其用途 |
| KR20200069364A (ko) | 2017-10-24 | 2020-06-16 | 마젠타 테라퓨틱스 인코포레이티드 | Cd117+ 세포의 고갈을 위한 조성물 및 방법 |
| WO2019084057A2 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| KR102835308B1 (ko) * | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202190986A1 (ru) | 2018-11-26 | 2021-12-14 | Фоти Севен, Инк. | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit |
| WO2020219748A2 (en) * | 2019-04-24 | 2020-10-29 | Magenta Therapeutics, Inc. | Anti-cd117 antibodies and uses thereof |
| EP4022051A4 (en) | 2019-08-29 | 2024-01-10 | Beam Therapeutics Inc. | COMPOSITIONS AND METHODS FOR NON-TOXIC CONDITIONING |
-
2022
- 2022-12-16 EP EP22843648.1A patent/EP4448573A1/en active Pending
- 2022-12-16 MX MX2024007317A patent/MX2024007317A/es unknown
- 2022-12-16 CA CA3240527A patent/CA3240527A1/en active Pending
- 2022-12-16 AU AU2022409748A patent/AU2022409748A1/en active Pending
- 2022-12-16 WO PCT/EP2022/086452 patent/WO2023111311A1/en not_active Ceased
- 2022-12-16 JP JP2024536163A patent/JP2024546996A/ja active Pending
- 2022-12-16 US US18/719,780 patent/US20250057951A1/en active Pending
- 2022-12-16 KR KR1020247023745A patent/KR20240115920A/ko active Pending
- 2022-12-16 IL IL313568A patent/IL313568A/en unknown
-
2024
- 2024-06-28 ZA ZA2024/05110A patent/ZA202405110B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024546996A5 (enExample) | ||
| JP6993699B2 (ja) | ヒトインターロイキン－２に対する免疫刺激性ヒト化モノクローナル抗体及びその融合タンパク質 | |
| CN104105708B (zh) | PDGF受体β结合多肽 | |
| CN114341189A (zh) | 全新il-15前药及其应用 | |
| ES2774422T3 (es) | Anticuerpos para IL-21 | |
| WO2019080872A1 (zh) | 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途 | |
| EP4192872B1 (en) | Proteins binding nkg2d, cd16 and egfr | |
| WO2021062406A1 (en) | Cytokine prodrugs and dual-prodrugs | |
| JP2017535257A (ja) | 免疫応答およびがん治療の増強に使用するための組成物および方法 | |
| WO2020168555A1 (zh) | Cd3抗原结合片段及其应用 | |
| TW202110894A (zh) | 抗alk2抗體 | |
| JP2021508247A (ja) | 抗フリズルド抗体及び使用方法 | |
| TW201520226A (zh) | 泛－ｅｌｒ＋ｃｘｃ趨化因子抗體 | |
| TW202104261A (zh) | 三特異性結合蛋白、方法及其用途 | |
| CN116323667A (zh) | 结合PSMA和γ-δT细胞受体的抗体 | |
| CN116323671A (zh) | 具有增加的选择性的多靶向性双特异性抗原结合分子 | |
| WO2022223001A1 (zh) | 双特异性多功能融合多肽 | |
| TW202440636A (zh) | Ｃｄ１９／ｃｄ３８多特異性抗體 | |
| TW202102544A (zh) | 雙特異性抗體 | |
| JP2025500288A5 (enExample) | ||
| KR20180021875A (ko) | 다중특이적 결합 단백질 | |
| CN119855830A (zh) | Ang-2/vegf抗体及其用途 | |
| US20250313644A1 (en) | Antibodies capable of specifically binding tl1a and use thereof | |
| JP7849919B2 (ja) | ヒトｄｒ３に特異的に結合する抗体及びその用途 | |
| US20250152710A1 (en) | Modified primary immune cells for induction or enhancement of immunotherapy |